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Background. No study has used whole-genome sequencing (WGS) to investigate risk factors for Clostridium difficile (CD) trans-
mission between cases, or assessed the impact of recent acquisition on patient outcome.
Methods. This 20 month retrospective cohort study included consecutive cytotoxin-positive diarrheal samples, which underwent 
culture, ribotyping, and WGS (Illumina). Sequenced isolates were compared using single nucleotide variants (SNVs). Independent 
predictors of acquisition from another case, onward transmission, 120-day recurrence, and 30-day mortality were identified using 
logistic regression with backwards elimination.
Results. Of 660 CD cases, 640 (97%) were sequenced, of which 567 (89%) shared a ribotype with a prior case, but only 227 (35%) 
were ≤2 SNVs from a prior case, supporting recent acquisition. Plausible (<2 SNVs) recent ward-based acquisition from a symptom-
atic case was more frequent in certain ribotypes; 64% (67/105) for ribotype-027 cases, compared with 11% (6/57) for ribotype-078. 
Independent risk factors (adjusted P < .05) for CD acquisition included older age, longer inpatient duration, and ribotype; these 
factors, and male sex, increased onward transmission. Patients with a plausible donor had a greater risk of recurrence (adjusted P = 
.001) and trended towards greater 30-day mortality (adjusted P = .06). Ribotype had no additional mortality or recurrence impact 
after adjusting for acquisition (P > .1).
Conclusions. Greater transmission of certain lineages suggests CD may have different reservoirs and modes of transmission. 
Acquiring CD from a recent case is associated with poorer clinical outcomes. Clinical characteristics associated with increased 
healthcare-associated CD transmission could be used to target preventative interventions.
Keywords. Clostridium difficile; whole-genome sequencing; outcome.
Clostridium difficile (renamed Clostridioides difficile) infec-
tion (CDI) is the most common hospital-associated infection 
in the United States [1] and challenges healthcare providers 
worldwide. CDI is associated with increased all-cause 30-day 
mortality, and particular strain types, for example BI/NAP1/
ribotype-027, have been associated with worse clinical out-
comes [2, 3].
The temporal and spatial epidemiology of C. difficile strains 
is frequently monitored using ribotyping [4] in Europe [5] and 
pulsed-field gel electrophoresis [6] and ribotyping in North 
America. Whole genome sequencing (WGS) is a highly dis-
criminatory fingerprinting technique that has been used to 
demonstrate the inter-continental spread of recently evolved 
clones (BI/NAP1/ribotype-027) [7], and to determine strain 
transmission between CDI cases [8–10]. Previous epidemiolog-
ical studies have shown that typically only a third of new CDI 
cases are acquired from a symptomatic donor [9, 11, 12], but 
no study has compared the clinical attributes and strain types 
of cases with and without healthcare-associated acquisition, as 
defined by WGS.
The aim of this study was to find out whether using a WGS-
based analysis of C. difficile strains, rather than less-discrimi-
natory techniques such as ribotyping, reveals insights into the 
patient and strain characteristics most closely associated with 
CDI transmission and outcome. We investigated C.  difficile 
transmission between symptomatic cases within a UK region, 
diagnosed via a reference method (cell cytotoxicity), using both 
ribotyping and WGS. We determined patient and strain risk 
factors for both transmitting the infection onwards and acquir-
ing C. difficile from a prior symptomatic case. We assessed the 
clinical consequences of case-to-case transmission by investi-
gating the likelihood of CDI recurrence and death in patients 
with/without a probable donor.
METHODS
Leeds Teaching Hospitals’ NHS Trust’s laboratory provides 
diagnostic services for all inpatient and community care in 
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the metropolitan area of Leeds, UK (population 750 000). It 
comprises 3 large teaching hospitals and numerous smaller 
community care providers. During this study, Leeds Teaching 
Hospitals’ infection control policy stipulated that any patient 
with ≥1 episode of unexplained diarrhea should be isolated and 
tested for CDI [13]. Patients were source-isolated from the day 
of onset of diarrhea to being either >48 hours symptom-free or 
discharged from hospital. Standard CDI treatment during this 
period was oral metronidazole for non-severe cases and oral 
vancomycin for severe cases (total white cell count >15.0x109/L, 
serum creatinine >50% above baseline, or evidence of colitis).
Consecutive diarrheal samples submitted for CDI testing and 
confirmed as toxin-positive by a cell cytotoxicity assay were 
cultured from a single colony, ribotyped [4], and sequenced 
using Illumina technology [9]; the samples included any repeat 
positives >7  days later from the same patient. Samples were 
compared using ribotype and differences in single nucleotide 
variants (SNVs) obtained from maximum likelihood phylog-
enies (Supplementary Methods). Sequences generated during 
this study can be found on the NCBI short read archive under 
BioProject PRJNA317528 (http://www.ncbi.nlm.nih.gov/
bioproject/PRJNA317528).
CDI cases were defined as the first culture-positive C.  diffi-
cile sample from each cytotoxin-positive patient, plus repeat cul-
ture-positive samples >10 SNVs distinct from all prior samples 
(extremely unlikely to arise through mutation during the study) [8, 
9, 14]. For each case, data were collected on sex; age; all inpatient 
episodes in the 6 months before and after each sample, including all 
ward-stays, day-case procedures, dialysis, and chemotherapy atten-
dances; time between stool sampling and source isolation; home 
postcode district; general practice location; severity biomarkers at 
diagnosis (summarized as severity score 0–3; one point each for 
age >65 years, peak creatinine >176μmol/L, and peripheral blood 
white cell count >20 000 cells/µL) [15]; recurrence (occurring in 
the next 120 days); and all-cause 30-day mortality. Recurrent infec-
tion was defined as a repeat cytotoxin-positive sample >14 days 
after the first positive sample (reliable information was not availa-
ble about symptom resolution between samples). Consensus defi-
nitions were used for community-associated (CA), indeterminate 
(I), community-onset healthcare facility–associated (CO-HCFA), 
and hospital-onset healthcare facility–associated (HO-HCFA) CDI 
(Supplementary Figure S1) [3].
For each new sequenced case (n  =  640), we considered all 
previous case strains (including repeat positives within individ-
uals) as potential transmission sources. Using rates of C. difficile 
evolution and within-host diversity, direct transmission was 
considered plausible where a prior “donor” isolate was within 
0–2 SNVs of a “recipient” [9]. Cases within 3–10 SNVs were 
likely to share a common source in the last 5 years, but direct 
transmission was unlikely. Cases >10 SNVs from all previous 
cases were considered genetically distinct and unlikely to share 
a common source with another case during the study.
Statistical Methods
Univariable associations between these factors and cases having 
acquired C. difficile from a previous, closely genetically-related 
case or having transmitted CDI onwards (≤2 SNV threshold) 
were investigated using Kruskal-Wallis/rank-sum (continuous 
factors) and chi-squared/exact (categorical factors) tests. For 
multivariable logistic models for acquisition, transmission, 120-
day recurrence, and 30-day mortality, severity score (missing 
in n = 124 [19%] where blood tests were not done) and source 
isolation at onset (missing in n = 269 [42%]; 150 pre–January 
2011, when this was not collected, and 119 post–January 2011, 
due to poor documentation) were imputed multiply (50 times) 
using both chained estimating equations [16] (Stata version 
14.1; including all factors above and all four outcome variables) 
and boxcox-transforming continuous variables for normality. 
Independent predictors were selected using backwards elimi-
nation (exit P > .1 to fit an exploratory model) using fractional 
polynomials to investigate non-linearity [17]. Independent 
effects of each ribotype with >25 cases (vs all other ribotypes) 
were considered for inclusion in main models. Sensitivity anal-
yses included ribotype as an 8-level factor (7 common vs others 
combined), together with all factors identified as independently 
prognostic in any model or all other factors.
The study was approved by the Berkshire Research Ethics 
Committee (10/H0505/83) and the Health Research Authority 
(8-05[e]2010).
RESULTS
From 1 August 2010 to 24 April 2012, of 16 873 tested diarrheal 
samples from hospital and community patients in the Leeds 
region, 888 (5%) were C. difficile cytotoxin-positive, represent-
ing 660 CDI cases in 625 patients (excluding repeats ≤10 SNVs). 
A total of 831 C. difficile isolates were successfully sequenced, 
representing 640/660 (97%) cases (Supplementary Figure S2).
Median age at diagnosis was 76  years (inter-quartile 
range [IQR] 62–84), and 389 (59%) cases were female patients. 
The incidence of healthcare-associated CDI was 4.2 HO-HCFA 
and CO-HCFA infections per 10 000 overnight stays. The inci-
dence of community-associated CDI was 143 CA and I infec-
tions per 100 000 Leeds community per annum. Incidence 
declined during the study period (Supplementary Figure  S3). 
Thirty-day all-cause mortality was 19% (124/660) for all cases. 
The most frequent ribotypes were 027 (multi-locus sequence 
type, ST1; 106 [16%] cases), 015 (ST10/ST44/ST45; 64 [10%]), 
and 078 (ST11; 58 [9%]). The rate of identification of genetically 
distinct strains (>10 SNVs from previous cases) was approxi-
mately constant during the study (Supplementary Figure S4).
CDI Recurrence
Sequential samples were analyzed for CDI cases with ≥120 days 
of follow up (1 August 2010 to 26 December 2011). Removing 
repeat samples ≤10 SNVs within 14  days of the first sample, 
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114/539 (21%) first CDI cases in this period had a recurrence. 
Of these, 95 (83% of recurrences, 18% of first CDI cases) 
were within 0–2 SNVs (ie, probable relapse) and 16 (14% of 
recurrences, 3% of first CDI cases) were >10 SNVs (ie, prob-
able re-infection). The duration between the first sample and 
recurrence was a median 26 days (IQR 22–40; range 15–103) 
for 0–2 SNVs repeats, and 32 days (IQR 27–65; range 14–93) 
for >10 SNVs repeats (P = .06). The remaining 3 recurrences 
were 3 SNVs distant, occurring 24–91 days following the first 
sample. Of the 114 first CDI cases with recurrences, 98 (86% 
of recurrences, 18% of first cases) had recurrent infection with 
the same ribotype; 1 patient had reinfection with a genetically 
distinct (1340 SNVs distant) C.  difficile strain of the same 
ribotype.
C. difficile Transmission From Prior Cases
Out of the new cases, 567 (89%) had the same ribotype as at 
least one previous CDI in the study population, but only 227 
(35%) were 0–2 SNVs from a previous isolate, suggesting recent 
acquisition from the symptomatic population, while 286 (45%) 
were >10 SNVs from all prior isolates (Table  1). These pro-
portions were similar when restricting to cases from January 
2011 onwards (175/449 [39%] 0–2 SNVs and 176/449 [39%] 
>10 SNVs, P = .20), demonstrating there was no significant dif-
ference in the proportion of cases with a recent donor when 
accounting for the potentially reduced pool of donors in the 
first months of the study.
Only 115 (18%) new CDI cases had any prior direct ward 
contact (same ward, same day) with a 0–2 SNV donor; this con-
tact was for a median of 8 days (IQR 4–16; range 1–59), with a 
median of 20 days (IQR 6–45; range 1–191) between the donor’s 
most recent positive and the recipient’s first positive sample 
(counting the most recent donor if multiple donors were iden-
tified). Other potential transmission routes are summarized in 
Table 1.
Impact of Acquisition on Clinical Outcomes
All-cause 30-day mortality was 27% (62/227) for patients with a 
previous potential donor, but only 12% (34/286) for those with 
genetically distinct strains (P  <  .001). Recurrence (>14  days 
after first test) was also more frequent in cases with any poten-
tial donor (29%, 65/227) versus those without (16%, 47/286; 
P  =  .001). The association between acquisition and mortality 
did not persist after adjusting for other independent predictors 
(Table  2; P  =  .06), but there was an independent association 
between acquisition and recurrence (P  <  .001). Importantly, 
other than ribotype-020 marginally increasing the risk of recur-
rence vs all other ribotypes combined (P =  .06), there was no 
additional impact of ribotype on either mortality or recurrence 
after adjusting for the (stronger) impact of acquisition itself 
(P >  .1); thus, any excess risk of adverse outcomes associated 
univariably with specific lineages (ribotype-027 in particular, 
with univariable P  <  .001 for associations with mortality and 
recurrence) was mediated through acquisition from a previous 
symptomatic donor.
Risk Factors for Acquiring CDI From a Previous Case
The factors most strongly univariably associated with having a 
previous potential donor (0–2 SNVs) were older age, origin of 
infection (CA/I/CO-HCFA/HO-HCFA), more inpatient days 
in the 12 weeks pre-diagnosis, higher severity score, and ribo-
type (Table 3). More recent hospital exposures were associated 
with greater proportions of CDIs closely related to a prior case 
(Supplementary Figure  S5, Supplementary Table  S3), both at 
SNV thresholds consistent with direct and recent indirect trans-
mission (suggesting these cases arose from a reduced hospital 
reservoir of strains). The range of ribotypes causing CDI was 
broad regardless of healthcare or community origin of infec-
tion, although ribotype-027 was particularly associated with 
close healthcare exposure (P = .02 vs other ribotypes combined; 
Supplementary Figure S6).
Table 1. Genetic Relatedness of 640 New Clostridium difficile Infection Cases to Any Previous Isolate
Type of Relationship/Contact Same Ribotype 0 SNV 0–2 SNV 3–10 SNV 0–10 SNV
Relationship to all previous study isolates at this threshold 567 (89%) 162 (25%) 227 (35%) 127 (20%) 354 (55%)
Genetically linked to any previous case on the same ward at the same 
time
164 (26%) 91 (14%) 115 (18%) 9 (1%) 124 (19%)
 Within plausible infectious and incubation periodsa 139 (22%) 84 (13%) 105 (16%) 6 (1%) 111 (17%)
Genetically linked to any previous case on the same ward at a different 
time
144 (23%) 20 (3%) 30 (5%) 34 (5%) 64 (10%)
 Within 4 wk 54 (8%) 13 (2%) 16 (3%) 9 (1%) 25 (4%)
Plausible community contact 83 (13%) 8 (1%) 13 (2%) 8 (1%) 21 (3%)
 Shared general practice 27 (4%) 4 (1%) 10 (2%) 1 (0%) 11 (2%)
 Postcode district 77 (12%) 8 (1%) 11 (2%) 9 (1%) 20 (3%)
Genetically related but no contact of any kind identified 176 (28%) 43 (7%) 69 (11%) 76 (12%) 145 (23%)
 CA/I 67 (10%) 12 (2%) 21 (3%) 32 (5%) 53 (8%)
Prior contact considered in order shown (same ward same time (direct), same ward different time (spore), community) with the exception of any spore contamination lasting <28 days which 
was considered more plausible than direct transmission outside 56-day donor infectious period and 90-day recipient incubation periods.
Abbreviations: CA, community associated; CDI, Clostridium difficile infection; I, indeterminate; SNV, single nucleotide variants.
aFifty-six–day donor infectious period and 90-day recipient incubation [18].
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The proportion of cases with potential donors at differing 
levels of genetic relatedness varied markedly according to CDI 
ribotype (Figure 1, Supplementary Table S4). The vast majority 
of ribotype-027 (102/105 [97%]) and ribotype-078 (54/57 [95%]) 
CDIs had a previous case within 0–10 SNVs; however, genetically 
close matches (0–2 SNV) occurred in 94% (99/105) and 46% 
(26/57), respectively. Furthermore, 64% (67/105) of ribotype-027 
but only 11% (6/57) of ribotype-078 cases had shared time on a 
ward with a potential donor ≤2 SNV, supporting greater rates of 
hospital-based acquisition for ribotype-027 compared with ribo-
type-078. Other common ribotypes (e.g. 015 and 002) were much 
more genetically diverse; thus, lower proportions of these CDIs 
had prior strains within 0–10 SNVs (56% [35/62] ribotype-015 
and 51% [28/55] ribotype-002), 0–2 SNVs (19% [12/62] and 27% 
[15/55], respectively), and, particularly, 0–2 SNVs with ward con-
tact (3% [2/62] and 15% [8/55], respectively).
In a multivariable analysis, the odds of acquiring CDI from 
a previous symptomatic donor (0–2 SNVs) remained inde-
pendently higher for specific ribotypes (particularly 027; to a 
lesser extent, 078/014/020/001/072), older individuals, and those 
with more inpatient days in the preceding 12 weeks; as expected, 
risk was lower in the first study month, where fewer previous 
cases had been sequenced (Table 2). There was no independent 
effect of origin of infection (CA/I/CO-HCFA/HO-HCFA) after 
adjusting for these factors (P = .71), which was plausibly better 
explained by total inpatient days in the last 12 weeks rather than 
time since last exposure, categorized as per surveillance criteria.
Risk Factors for Onward Transmission
A total of 228 (36%) CDI cases were potential donors (0–2 
SNVs) to ≥1 subsequent cases. The factors most strongly 
univariably associated with being a potential donor were older 
age, male sex, earlier diagnosis in the study period, more inpa-
tient days during the 12 weeks before diagnosis, higher severity 
score, and ribotype (Table 4). In 20/115 (17%) recipients, the 
most plausible transmission event (using the most recent donor 
if multiple donors were identified) followed a donor’s second or 
third diarrheal sample, a median of 49 days (IQR 21–95; range 
8–129) after the initial test. Overall, 45/115 (39%) of the most 
plausible donors had recurrent infections.
In a multivariable analysis, the odds of onwards transmis-
sion to a new symptomatic CDI case (0–2 SNVs) remained 
independently higher for specific ribotypes (particularly 027; 
to a lesser extent, 078/014/020/002/001/072), older individu-
als, men, and those with more inpatient days in the preceding 
12 weeks; as expected, odds decreased slightly over the study 
period (Table  2). After adjusting for these factors, there was 
no independent effect of donor origin of infection (P = .93) or 
inpatient days post-diagnosis (P = .47).
CONCLUSIONS
Our study identified risk factors connected with healthcare-as-
sociated transmission of CDI, and measured the clinical con-
sequences of recent C. difficile acquisition from a symptomatic 
case, having robustly defined genetic relatedness between cases 
using WGS. We examined a large cohort of cases using a sensi-
tive approach to sampling and diagnosis based on toxin testing, 
which has been shown to have a high predictive value for true 
CDI [19, 20]. By combining WGS and conventional ribotyping, 
we found that genetic relatedness of strains to previous cases 
varies significantly according to ribotype, suggesting C. difficile 
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Figure 1. Genetic relatedness to previous Clostridium difficile infection cases by ribotype (if >25 cases). Abbreviation: SNV, single nucleotide variants.
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lineages may have different reservoirs and modes of transmis-
sion. Interestingly, however, we did not demonstrate an inde-
pendent relationship between ribotype and adverse outcome, 
as some previous studies have shown; recurrence and mortality 
were more strongly associated with strain acquisition from a 
recent case than with strain type.
We found that predictors of recent strain acquisition and 
onward transmission included more inpatient days during the 
12 weeks before diagnosis, older age, and certain ribotypes. 
These data could help to identify a high-risk population for 
healthcare-associated strain acquisition that could be used 
when planning future preemptive C. difficile interventions, such 
as vaccination [21] or prophylaxis [22]. Interestingly, the total 
number of days spent in hospital in the 12 weeks prior to infec-
tion was more closely associated with strain acquisition than 
conventional community vs. hospital definitions [3].
Our results provide new evidence that certain C.  difficile 
ribotypes have higher levels of in-hospital transmissibility. 
Specifically, ribotype-027 strains were predominantly clonal, 
with approximately two-thirds of ribotype-027 CDIs having 
Table 4. Characteristics of Genetically-matched and Distinct Potential Donors
Factor
All New Cases
0–2 SNV Potential Donors 
to Any Subsequent Casea
Subsequent Case 3–10 
SNV
All Subsequent Cases 
>10 SNV
P  Value 0–2 vs 
3–10 vs >10 SNVs
P  Value 0–2 vs >2 
SNVsN = 640 N = 228 (36%) N = 131 (20%) N = 281 (44%)
Predictors
 Female 376 (59%) 117 (51%) 78 (60%) 181 (64%) P = .01 P = .004
 Age, years 76 (61–84) 80 (70–87) 74 (58–83) 71 (53–83) P < .001 P < .001
 Days from start of 
study to sample
255 (126–404) 224 (112–342) 255 (111–374) 335 (158–495) P < .001 P < .001
 Type of CDI
  CA 121 (19%) 27 (12%) 36 (27%) 58 (21%) P < .001 P = .002
  I 46 (7%) 13 (6%) 9 (7%) 24 (9%)
  CO-HCFA 126 (20%) 37 (16%) 29 (22%) 60 (21%)
  HO-HCFA 347 (54%) 151 (66%) 57 (44%) 139 (49%)
 Inpatient on day of 
diagnosis
511 (80%) 193 (85%) 100 (76%) 218 (78%) P = .08 P = .02
 Inpatient days in the 
12 wk pre-diagnosis
16 (4–40) 21 (9–45) 10 (1–26) 14 (3–38) P < .001 P < .001
 Source isolation 
on the day of 
symptom onsetb
177/246 (72%) 67/100 (67%) 29/39 (74%) 81/107 (76%) P = .36 P = .15
 Ribotype (if >25 cases)
  027 105 (16%) 98 (43%) 4 (3%) 3 (1%) P < .001 P < .001
  015 62 (10%) 12 (5%) 24 (18%) 26 (9%) P < .001 P = .005
  078 57 (9%) 26 (11%) 28 (21%) 3 (1%) P < .001 P = .10
  002 55 (9%) 16 (7%) 17 (13%) 22 (8%) P = .13 P = .29
  014 49 (8%) 19 (8%) 2 (2%) 28 (10%) P = .01 P = .63
  020 38 (6%) 15 (7%) 9 (7%) 14 (5%) P = .66 P = .61
  001/072 29 (5%) 13 (6%) 4 (3%) 12 (4%) P = .53 P = .32
  Other 245 (38%) 29 (13%) 43 (33%) 173 (62%) P < .001 P < .001
Outcomes
 Clostridium difficile severity score (N = 516 cases)
  0 119 (23%) 18 (10%) 27 (26%) 74 (33%) P < .001 P < .001
  1 268 (52%) 110 (59%) 52 (50%) 106 (47%)
  2 112 (22%) 48 (26%) 24 (23%) 40 (18%)
  3 17 (3%) 10 (5%) 2 (2%) 5 (2%)
 Inpatient days 
in the 12 wk 
post-diagnosis
16 (4–38) 19 (7–41) 16 (3–41) 13 (3–33) P = .04 P = .01
 >1 positive sample 158 (25%) 73 (32%) 32 (24%) 53 (19%) P = .003 P = .001
 Recurrent CDI (≥14 d) 136 (21%) 60 (26%) 28 (21%) 48 (17%) P = .04 P = .02
 30-d mortality 120 (19%) 56 (25%) 18 (14%) 46 (16%) P = .02 P = .005
Numbers show N (%) or median (IQR), and univariable Kruskal-Wallis (continuous variable) or chi-squared (categorical) tests. Fisher’s exact tests were used where any cell percentage was 
<5% or any frequency was <5. For ribotypes each comparison is that specific ribotype vs all others pooled.
Abbreviations: CA, community associated: CDI, Clostridium difficile infection; CO-HCFA, community-onset healthcare facility–associated; HO-HCFA, hospital-onset healthcare facility–asso-
ciated; I, indeterminate; SNV, single nucleotide variants.
aincluding any case with a subsequent case within the 0–2 SNV threshold as a potential donor as the specific transmission route is unknown. 
bApplicable only to hospital-onset cases: collected from January 2011 where data was available in clinical documentation.
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recent ward contact with a genetically matched case. This epi-
demic ribotype has been associated with more frequent poor 
outcomes and is known to be a recently evolved clone [7, 23]. 
Conversely, ribotype-078, a strain also associated with poor 
outcomes [24, 25], was largely clonal, but only 11% of ribo-
type-078 CDIs occurred in patients with recent ward contact 
with a genetically matched case. Other authors have also shown 
low patient-to-patient transmission for this strain [26]. C. diffi-
cile ribotype-078 is commonly found in livestock [27, 28], hence 
food and farm exposure are potential alternative environmental 
sources [29–31]. Notably, other common disease-causing lin-
eages (eg, 015, 002) demonstrated few genetic matches, so were 
unlikely to have been recently acquired from a common source.
We show that 30-day mortality and 120-day disease recur-
rence were each more likely in cases where CDI was plausibly 
acquired from a recent donor. The association between recent 
acquisition and recurrence persisted after adjusting for other 
important factors, including age and ribotype; hence, this associ-
ation was not due to confounding by ribotype-027 in particular. 
The association between recent acquisition and outcome may 
reflect a host contribution (eg, multiple comorbidities) predis-
posing a patient to both the acquisition and the poor outcome. 
Nevertheless, these findings strongly support the importance of 
infection control interventions in targeting symptomatic CDI 
cases to reduce the risk of transmission to vulnerable patients, 
and so prevent particularly poor outcomes in these individu-
als. Furthermore, in an era where nosocomial CDI incidence is 
increasingly viewed as a healthcare quality indicator [32], our 
data suggest that evidence demonstrating control of in-hospital 
C. difficile transmission (ie, lack of strain-relatedness between 
cases) could be used as a specific measure of prevention and 
control effectiveness.
Our study has several limitations. In particular, it is impos-
sible to confirm patient-to-patient C.  difficile transmission 
retrospectively, even with detailed epidemiological data and 
WGS. The few sequence failures may have led to donor/
recipient genetic relationships being missed. Transmission 
events outside the geographical boundaries of Leeds could 
also have been missed. We did not examine asymptomatic 
carriers and, therefore, our results apply only to transmission 
leading from and to disease; there is growing evidence that 
asymptomatic carriers may play a key role in wider C. difficile 
transmission [12, 33, 34]. However, as WGS-matched sam-
ples from the entire study period were considered as possible 
donors, the influence of clinically significant (but unknown) 
intermediate carriers has been accounted for, as two cases 
related by a common source were still linked to each other in 
the study. Furthermore, a low threshold for patient sampling 
and automatic C. difficile testing of diarrheal specimens will 
have enhanced our detection of possible C.  difficile donors; 
such UK-recommended practice has been associated with a 
marked decrease in CDI incidents [5, 35]. The incidence of 
ribotype-027 has decreased in the UK since the study period; 
the proportion of cases with a donor (or recipient) may 
be lower if the study is repeated. Data for some potentially 
influential factors were incomplete or not available (includ-
ing proton-pump inhibitor use, antibiotic use, and co-mor-
bidities), and so we have not considered these in our main 
analyses. Understanding the possible role of antibiotic use in 
transmission/acquisition of C.  difficile is complex, not least 
given heterogeneity of exposure (including polypharmacy). 
Interestingly, antibiotic use in the 7 or 90  days before diag-
nosis was not strongly associated with either transmission or 
acquisition from a previous symptomatic donor (both P > .2; 
Supplementary Table S5) in patients for whom these data were 
available. Lastly, data were not available on diarrhea severity 
or duration; however, CDI severity criteria and repeat tests 
were used as proxies for these.
In summary, WGS and detailed epidemiological data demon-
strate that acquisition of a C. difficile strain that caused a previous 
symptomatic case is associated with poorer clinical outcome. 
Targeting preemptive interventions to patients at high risk of 
being donors or recipients will likely further reduce C. difficile 
transmission and infection rates within healthcare institutions. 
This will help to improve patient experiences and outcomes. 
Notably, we also demonstrated variable healthcare-associated 
transmission of C. difficile strain types, suggesting CDI is not 
a homogeneous entity, but is likely to have different reservoirs 
and modes of transmission.
Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases online. 
Consisting of data provided by the authors to benefit the reader, the posted 
materials are not copyedited and are the sole responsibility of the authors, 
so questions or comments should be addressed to the corresponding author.
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